PTO Rejects Gilead's Patents For HIV Drug

Law360, New York (January 24, 2008, 12:00 AM EST) -- The U.S. Patent and Trademark Office has rejected Gilead Sciences Inc.'s four patents related to HIV/AIDS medication, finding that the company neglected to cite prior art when securing the patents.

The PTO issued so-called nonfinal rejections that sided with the nonprofit Public Patent Foundation's challenge of the four key patents for Viread, an HIV/AIDS treatment known generically as tenofovir disoproxil fumarate.

“We are extremely pleased that the Patent Office has agreed with us that Gilead's TDF patents are invalid,” said Dan Ravicher, executive director of PUBPAT,...
To view the full article, register now.